Janet Sasso, Information Scientist at CAS, provides an overview of the antibody drug conjugate market and its potential in oncology. Antibody-drug conjugates (ADCs) are a class of targeted biopharmaceuticals that combine the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, a combination attracting growing attention in the CAS Content Collection. By delivering […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!